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Abstract
Purpose of Review This review examines the influences of active vitamin D on ‘developmental’ haematopoiesis and the immune
cells produced. Haematopoiesis gives rise to the platelets, erythrocytes and a wide range of immune cell types each of which
performs a specific role to protect the organism from a myriad of infectious agents. The newly produced immune cells, for
example, monocytes, dendritic cells and Tand B lymphocytes, are activated in response to the presence of an infectious agent and
differentiate further to perform their roles.
Recent Findings Binding of 1α,25-dihydroxyvitamin D3, the most active metabolite of vitamin D3, to its receptor, the vitamin D
receptor, regulates the expression of very many different genes and therefore a mode(s) of action of vitamin D relates to the
regulation of expression of cell-specific genes. The haematopoietic cytokines are essential regulators of haematopoiesis and the
further maturation and functionality of the immune cell types.We now know that some cytokines also instruct the development of
a particular type of blood cell.
Summary Vitamin D influences the ‘early’ development of monocytes and invariant natural killer T cells and the further
maturation of some immune cell types. Findings regarding the regulation of gene expression have revealed that there are links
between the actions of vitamin D and cytokines. Whilst we do not have as yet an entirely clear picture on this matter, there are
benefits to ‘health’ of the immune system from vitamin D supplementation.
Keywords VitaminD . Haematopoiesis . Immune cells . Haematopoietic cytokines . VitaminD and health
Introduction
A clear picture of the architecture of the haematopoietic cell
system is vital to developing an understanding of the role of
vitamin D in haematopoiesis. For many years, investigators
have generally used tree-like diagrams to depict the ancestry
of the different types of the haematopoietic cells: this type of
model set a paradigm for the behaviour of tissue-specific stem
cells, such as those of the small intestinal mucosa. An under-
lying principle is that developing cells are restricted to making
a choice between just two fates at any particular time as argued
by Holzer in 1979 [1]. With regard to this type of model,
haematopoietic progenitor cells (HPCs), the progeny of the
pluripotent haematopoietic stem cells (HSCs), follow pre-
scribed routes to each end cell type. They undergo binary
choices in a stepwise manner to restrict their fate to just one
option [2]. Commitment to maturation towards a functional
cell type is the final stage in this process.
However, our understanding of the nature of HSCs and
their development has changed radically to accommodate
many recent findings leading to revision of the aforemen-
tioned ‘classic’ model of haematopoiesis. In particular,
affiliation/commitment to just one cell lineage can occur at
the level of the HSC and therefore much earlier than investi-
gators envisaged in stepwise models. Instead of HSCs being a
homogeneous population of pluripotent cells, they are there-
fore a mixed population of cells with lineage affiliations/
biases. Human adult bone marrow CD34+ cells are many cells
with uni-potent myeloid or erythroid potential and some plu-
ripotent cells [3]. Our view of the process of decision-making
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by HSCs is that the end cell options are all available to the
HSC as a continuum whereby the HSC selects one and differ-
entiates towards that cell type. We have described the model
and the evidence that supports this viewpoint elsewhere [4••,
5, 6••] (Fig. 1). The model depicts close relationships between
particular cell types, as for tree-like models. In constructing
the model, we placed the cell lineages adjacent to one another
from the sets of options that are available to bi-potent and
oligo-potent progenitors, as revealed by cell culture experi-
ments. Whilst HSCs can ‘choose’ a cell l ineage,
haematopoiesis is a dynamic non-linear ecosystem because
HSCs and HPCs that have selected an option can still ‘change
their mind’ to differentiate towards a different fate.
Intrinsic events that govern fate options within
HSCs/HPCs, such as the accessibility of genes and the bind-
ing of appropriate transcription factors, clearly shape the pro-
duction of the various types of blood and immune cells.
However, a major change to our understanding of lineage
decision-making by HSCs/HPCs is that nurture by environ-
ment factors, and presumably proximal interactions with niche
cells, is equally important. Since the discovery of the various
haematopoietic cytokines, we viewed them as permissive to
cell behaviour in that they provide the signals that are essential
to the survival and proliferation of HSCs, their immediate
progeny and the mature end cell types [7]. In this manner
and for example, erythropoietin (Epo) supports erythropoiesis
[8], granulocyte colony-stimulating factor (G-CSF) supports
the development of granulocytes [9, 10], macrophage colony-
stimulating factor (M-CSF) the development of macrophages
and dendritic cells [11] and granulocyte/macrophage colony-
stimulating factor (GM-CSF) developing granulocyte and
macrophage cells [10, 12]. A major change to this viewpoint
is that recent studies have shown that these cytokines also
instruct lineage choice by HSCs/HPCs. Epo directs
multipotent HPCs towards erythropoiesis [13••], M-CSF in-
structs myeloid lineage fate in HSCs [14••] and macrophage
fate in granulocyte/macrophage progenitors [15] and G-CSF
and GM-CSF drive granulocyte/macrophage progenitors to
differentiate towards neutrophils [15, 16]. Moreover, HSCs
selectively express the receptors for Epo [17], M-CSF [14,
18, 19] and G-CSF [20] at their cell surface providing further
evidence to support the existence of lineage biases/affiliations
within these cells. Below, we examine the influence of vitamin
D taking into consideration the above substantial changes to
our understanding of haematopoiesis.
Vitamin D
Humans synthesise the most active metabolite of vitamin D3,
namely 1α,25-dihydroxyvitamin D3 (1,25D3, calcitriol), from
dietary precursors. In the skin, ultraviolet irradiation of 7-
dehyrocholesterol generates pre-vitamin D3 which, via non-
enzymatic and thermal means, is isomerised into cholecalcif-
erol (vitamin D3, D3). Bio-activation to 1,25D3 occurs first in
the liver, by vitamin D 25-hydroxylase (25-OHase or
CYP27A1) to calcidiol (25-hydroxyvitamin D, 25D3) and
subsequently in the kidney, by 25(OH)D-1α-hydroxylase
(1α-OHase or CYP27B1) [21]. In addition, hydroxylation at
C-1 occurs outside of the kidneys, for example, in immune
cells [22]. Investigators first identified 1,25D3 as playing a
role in the absorption and transport of calcium, phosphorous
and magnesium, and therefore essential to proper bone devel-
opment [23]. However, 1,25D3 has pleiotropic functions as to
regulating the transcription of around 3% of genes of the hu-
man genome through its nuclear receptor the vitamin D recep-
tor (VDR) [24]. We now view 1,25D3 as having a wide ‘hor-
monal’ role, including the maintenance of the blood cells,
cardiovascular, musculoskeletal, renal, nervous and adipose
systems.
The Influence of 1,25D3 on the Niches that Stem
and Progenitor Cells Reside in
The relative contribution of nature, all of the genes and their
actions, versus nurture, the environmental variables, and the
importance of their interplay to the status and behaviour of
cells is an age-old debate. Inherent events within HSCs/HPCs
and external influences that include cytokines and proximal
stromal cells both play a role in the proper conduct of
haematopoiesis. It is therefore important to bear in mind that
1,25D3 may influence one or both of these controls on blood
cell development.
Fig. 1 A continuummodel of haematopoiesis. The end cell options are all
available to the haematopoietic stem cell (HSC) as a continuum whereby
the HSC selects one and differentiates towards that cell type. HSC and
haematopoietic progenitor cells that have selected an option can still
‘change their mind’ to differentiate towards a different fate. There are
particular close relationships between the cell lineages, inferred from
the sets of options available to bi-potent and oligo-potent progenitors,
as revealed by cell culture experiments
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In the embryo, the development of blood cells occurs in
regions that include the aorta-gonad-mesonephros and foetal
liver. Haematopoietic stem and progenitor cells (HSPCs) arise
from the haemogenic endothelium in the dorsal aorta and
hedgehog and notch signalling, leading to Runx1 expression,
specifying the haematopoietic niche. Studies of the influence
of the 1,25D3 precursor D3 on zebrafish embryos, by means
of treatment or inhibiting the enzyme (Cyp2r1) that is required
for D3 hydroxylation (to 25D3), revealed that an accumula-
tion of D3 antagonises hedgehog signalling and impairs the
formation of the haemogenic vascular niche/its identity, lead-
ing to reduced HSPCs. This effect was specific to D3 and not
the active 1,25D3 [25]. Zebrafish studies have also shown that
that the availability of 1,25D3 during embryonic development
has an impact on the development of HSPCs. Loss of 1,25D3
biosynthesis, mediated by Cyp27b1, or loss of VDR reduced
the number of embryonic HSPCs and 1,25D3 acts in vitro and
ex vivo to stimulate proliferation of these cells. This effect was
independent of the calcium regulation of cell proliferation and
gene expression analysis indicated that an increase in CXCL8
(interleukin-8) in HSPCs plays an autocrine or paracrine role.
Similarly, the effect 1,25D3 on CD34+ve human umbilical
cord HSPCs ex vivo is to increase survival, proliferation and
the formation of multi-lineage colonies [26]. As mentioned
above, the foetal liver supports HSPC self-renewal and differ-
entiation, as does the adult organ in certain disease states when
there is reactivation of haematopoiesis. Thoughmicroenviron-
ment influences on definitive haematopoiesis in foetal liver
remain poorly understood, there is now an integrated map
for the human foetal liver haematopoietic cell lineages [27].
For haematopoiesis in adult mice, investigators observed
an effect of 1,25D3 on the environment that HSCs/HPCs re-
side in. Deletion of VDR in haematopoietic cells in VDR-
deficient mice (VDR−/−) did not affect the function of
HSCs/HPCs per se. In adult mice, haematopoiesis preferen-
tially takes place in the bone marrow and the VDR−/− mice
showed a significant increase in the number of HSCs/HPCs in
the spleen and increased primitive splenic haematopoiesis.
Investigators placed the mice on a rescue diet (containing
lactose, calcium and vitamin D) that corrects many of the
abnormalities in non-haematopoietic cells and this enabled
them to test whether the increased residence of HSCs/HPCs
in the spleen was due to loss of VDR in the haematopoietic
environment. The protocol reversed the changes seen in the
VDR−/− mice leading investigators to the conclusion that the
maintenance of bone calcium homeostasis is important to
adult haematopoiesis localising within the bone marrow [28].
HSCs/HPCs reside in precise anatomic niches in the bone
marrow and, for example, proximal mesenchymal cell popu-
lations regulate the self-renewal, proliferation and differentia-
tion of HSCs. The cytokine G-CSF releases HSCs/HPCs from
their niches in the marrow into the circulation by means of
osteoblast suppression, and the possible breakdown of
osteoblastic niches. Studies of VDR−/− mice have revealed
that VDR plays a role in G-CSF-induced osteoblast suppres-
sion and the subsequent mobilisation of HSCs/HPCs. The
mobilisation of these cells is severely impaired in VDR−/−
mice. β2-Adrenergic receptor agonists induce VDR expres-
sion in osteoblasts and the VDR is functional as to the expres-
sion of its downstream target gene the receptor activator of
NF-κB ligand (Rankl). 1,25D3 stabilizes VDR protein within
osteoblasts and sustains β2-adrenergic receptor agonist-
induced Rankl expression at a high level. The specific role
of Rankl expression in G-CSF-induced mobilization is still
unclear. Here, VDR is playing a role with G-CSF in the oste-
oblastic niche for HSCs/HPCs regarding the bone remodelling
events that are important to the release of HSCs/HPCs from
the bone marrow [29].
In addition to osteoblast niches, the bone marrow environ-
ments in which HSPCs develop are a mixture of cells, includ-
ing mesenchymal stem cells, endothelial cells, pericytes and
Schwann cells. We know that 1,25D3 affects a wide variety of
mature cell types and an effect of 1,25D3 on any of the many
bone marrow cell types may well in turn influence
haematopoiesis. 1,25D3 and its precursor 25D3 induce oste-
ogenic differentiation of human mesenchymal stem cells that
is important to haematopoiesis as above [30]. There is limited
information about the effect of vitamin D on bone marrow
endothelial progenitors and the endothelial cell system per
se. However, D3 supplementation of cultures improved the
viability of marrow-derived endothelial progenitors and their
capacity to form colonies [31]. There is still considerable
scope regarding future investigation of the effect of 1,25D3
on marrow stromal cells and the subsequent impact on steady-
state haematopoiesis, during stress and in disease states. For
example, bone marrow pericytes are different populations of
cells with different properties and they crosstalk with other
niche cellular components [32], and does 1,25D3 plays a role.
Similarly, 1,25D3 does affect non-myelinating and niche
Schwann cells that sustain the hibernation of HSCs, by
converting latent TGF-β to its active form [33].
The Direct Influence of 1,25D3 on Stem
and Progenitor Cell Developmental
VDR knockout mice have relatively normal numbers of eryth-
rocytes and white blood cells and therefore a lack of VDR
does not appear to have an overt effect on normal
haematopoiesis, as long as mice are kept in a pathogen-free
environment [34]. The exposure of mice with inactive VDR to
pathogens led to significant disturbances to the production of
blood cells. The disorder observed was the appearance of
chronic myeloid leukaemia-like cells, splenomegaly,
granulocytosis and thrombocytosis and reduced erythropoie-
sis [35]. In vitro studies have revealed that 1,25D3 and its
derivatives influence the progeny of HSCs and have largely
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focussed on an effect on myelopoiesis [36]. We have known
for many years that mouse myeloid leukaemia cells differen-
tiate towards monocytes in response to 1,25D3 ([37] and see
below), and that 1,25D3 drives normal blood monocytes to
differentiate into macrophages [38]. Early in vitro studies also
showed that 1,25D3 suppresses the formation of colonies by
granulocyte/macrophage progenitors (CFU-GM) and instead
induces colonies containing monocytes/macrophages (CFU-
M) [39]. Even so, it seems that 1,25D3 and VDR are facilitat-
ing monocyte/macrophage differentiation, rather than abso-
lutely required to sustain the generation of monocytes/
macrophages during steady-state haematopoiesis because
VDR knockout mice have relatively normal numbers of my-
eloid cells. It is important to bear in mind that majority of data
have been obtained from murine models, and that not all as-
pects of haematopoiesis in mice apply to humans [40]. There
are significant differences in the regulation of VDR expression
between mice and humans. The Vdr gene in mice has an
organization that is simpler than that in humans, and differ-
ences lie in the untranslated exons and their promoters [41]. In
consequence, ligand-activated VDR regulates the expression
of murine Vdr, whilst ligand-activated RARα regulates the
expression of human VDR rather than activated VDR [42, 43].
As considered above, it is important to bear in mind that M-
CSF can drive HSCs towards a myeloid fate and granulocyte/
macrophage progenitors to develop towards macrophages.
Does VDR cooperate with M-CSF either directly or indirectly
to this effect? We do not know the answer to this question
regarding the cell lineage choice by HSCs/HPCs. However,
1,25D3 does have an action on the M-CSF/M-CSF receptor
system as studies using bone marrow precursor cells, collected
by pre-treatment of murine bone marrow with 5-fluorouracil,
showed that 1,25D3, in a dose-dependent manner, caused a
rapid appearance of the M-CSF receptor in early precursor cells
and receptor expression was decreased in intermediate precur-
sors [44]. For monocytes stimulated to differentiate into den-
dritic cells by interleukin-4 and GM-CSF, 1,25D3 inhibited the
induction of differentiation, downregulated the surface expres-
sion of theM-CSF receptor and upregulated the secretion ofM-
CSF [45]. In this case, it is interesting that 1,25D3 interferes
with the differentiating action of GM-CSF. These findings point
to cooperation between VDR andM-CSF and that the outcome
appears to be dependent on the differentiation stage of cells.
In keeping with an influence of 1,25D3 on normal macro-
phage development is that the human earlymyeloid leukaemia
cell lines HL60, U937, THP-1 and MOLM-13 differentiate
towards macrophages when treated with 1,25D3 (reviewed
in [41]). Studies of mouse models of acute myeloid leukaemia
(AML) confirmed the differentiating and anti-leukaemia ac-
tion of 1,25D3 [46]. Regarding the anti-leukaemia action of
1,25D3, the cell lines and acute myeloid leukaemia cells arrest
their growth in G1 of cell cycle when they differentiate to-
wards macrophages. VDR regulates transcription from genes
that are important to both of these processes by forming a
dimer with the retinoic acid receptor (RXR) which binds to
the VDR response element of genes. 1,25D3 regulates the
expression of between 200 and 600 genes depending on the
cell type and either directly or indirectly [47, 48]. Some are
important to the cell cycle arrest that accompanies differenti-
ation, for example, the cyclin-dependent kinase inhibitor 1
p21Cip1 (alternatively p21Waf1) is a VDR target gene. Other
VDR-regulated genes encode macrophage features, such as
the surface protein cluster of differentiation (CD) 14 [49•,
50, 51]. VDR strongly regulates the gene that encodes the
24-hydroxylase enzyme that catabolises 1,25D3 to an inactive
metabolite as its promoter contains multiple vitamin D re-
sponse elements [52]. Presumably, this action of VDR
modulates/curtails the exposure of cells to 1,25D3.
The human promyeloid cell line HL60 is able to differen-
tiate towards neutrophils, in response to all-trans retinoic acid
(ATRA), and macrophages, in response to 1,25D3. Whilst
HL60 cells provide a good in vitro model system for investi-
gations of how an individual haematopoietic precursor cell
might choose between two options, we still do not have a
precise understanding of the events that control decision-
making by HL60 cells. Even so, ATRA and 1,25D3 appear
to play a role in the process. The effect of 1,25D3 on HL60
cells is very similar to the effect on myeloid colony formation
by myeloid progenitor cells and in keeping with HSCs/HPCs
that have selected cell lineage but can still change their mind.
When grown to a high cell density, HL60 cells spontaneously
differentiate into neutrophils and therefore ATRA enhances
neutrophil differentiation [50], and it seems that 1,25D3 di-
verts HL60 cells towards monocytes. So, how might this hap-
pen? Like VDR, the retinoic acid receptor (RAR) for ATRA
forms a dimer with RXR to facilitate granulocyte differentia-
tion and granulocytic differentiation in vitro is impaired in
haematopoietic cells lacking the isotypes RARα1 and
RARγ [51, 53]. HL60 cells ‘choosing’ whether to differenti-
ate towards monocytes or neutrophils might relate to compe-
tition between VDR and RAR for binding to RXR and the
relative balance of activity of VDR/RXR versus that of RAR/
RXR [48]. In this case, VDR and RAR do play a role in HL60
decision-making but the interaction between these two recep-
tors is more complex than just competition. There is
cooperativity between the actions of 1,25D3 and ATRA be-
cause RARα regulates the expression of VDR. The human
stem cell–like KG-1 has a high level of expression RARα and
does not respond to 1,25D3. RARα activation (by a specific
agonist) upregulates VDR expression and KG-1 cells then
respond to 1,25D3 by differentiating into monocytes. The
high level of inactive RARα in KG-1 cells is suppressing
VDR expression [42].
VDR-mediated diversion of myeloid differentiation to-
wards macrophages has a role in pathological conditions of
the bone marrow as shown for the initiation of myelofibrosis
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and subsequent osteosclerosis [54]. Myelofibrosis occurs in
myeloproliferative neoplasms and osteosclerosis is a compli-
cation. Investigators used a mouse model of myelofibrosis
whereby VDR+/+ HSPC were transplanted into VDR−/− mice
to show that the development of myelofibrosis was dependent
on macrophages. In the transplanted mice, donor-derived
macrophages proliferated together with recipient
myofibroblasts resulting in fibrotic tissues. Interfering with
the action of VDR, such as a low vitamin D diet, and macro-
phage depletion prevented the occurrence of fibrosis. In this
case, macrophages appear to support/influence the prolifera-
tion of collagen-producing myofibroblasts.
In addition to an effect of 1,25D3 on myelopoiesis,
1,25D3 status is important to the prenatal development
of invariant natural killer T (iNKT) cells as deficiency in
utero results in a significant reduction in the number of
these cells. Vitamin D is required before embryonic day
13 as revealed by timed pregnancies. Later intervention
with D3 or 1,25D3 did not correct the defect that is in-
trinsic to haematopoietic cells because vitamin D-deficient
bone marrow was defective in wild-type recipients regard-
ing the generation of iNKT cells. The investigators con-
cluded that the reduction in iNKT cells is due to increased
apoptosis of the precursors of these cells in the thymus,
and that 1,25D3 controls the number of just these cells in
the thymus. They also concluded that vitamin D deficien-
cy leads to epigenetic changes in iNKT cells because of
the failure to rescue the number of iNKT cells by later
exposure to 1,25D3 [55]. For iNKT cells, we also see
1,25D3 playing a role in cytokine action because
1,25D3 enhances the secretion of IL-4 by iNKT cells [56].
The proposal that the block in iNKT cell development
relates to epigenetic changes brings to attention whether
the pleiotropic effect of 1,25D3, namely the 200 to 600
genes regulated, relates to a global effect of 1,25D3 on
the epigenetic landscape. The landscape per se is important
to the binding of VDR to gene loci and VDR having bound
ligand interacts with the epigenome at multiple levels
(reviewed in [57]). VDR interacts with coactivator and
corepressor proteins that interact with chromatin modifiers
and re-modellers, including histone acetyltransferases,
deacetylases and methyl t ransferases . Regarding
haematopoietic cells, VDR binds at open chromatin loci
in the genome of the human leukaemia cell line THP-1
and treatment of these cells with 1,25D3 leads to a 30%
increase in the number of loci that are open [58•]. The
activities of histone acetyltransferases and histone methyl-
transferases are important to the action of liganded VDR
and histone deacetylase or DNA methyltransferase inhibi-
tors synergize to drive apoptosis of gastric cancer cells
[59]. Whilst the above information is from studies of cell
lines, it is likely that 1,25D3-driven changes to the epige-
nome are important to normal haematopoiesis.
The Influence of 1,25D3 on Immune Cells
The end cell product of ‘developmental’ haematopoiesis is a
very diverse range of immune cell types each of which per-
forms a specific role to protect the organism from the myriad
of different infectious agents. Whilst the information of the
effect of 1,25D3 on developmental haematopoiesis is some-
what limited, 1,25D3 does have an important influence on the
effectiveness of both innate and adaptive immunity. A normal
level of 1,25D3 is important to the ‘health’ of the immune
system as there are effects on macrophages/monocytes, den-
dritic cells, T lymphocytes, B lymphocytes and iNKTcells (as
above). The many effects and the potential benefits of 1,25D3
to immune function per se, and also immune reconstitution
post haematopoietic stem cell transplantation, have been
reviewed elsewhere [60•, 61•]. We therefore just present an
overview of some of the key influences of 1,25D3 (Fig. 2).
In addition to the ability of 1,25D3 to stimulate the differ-
entiation of monocytes to macrophages, the gene encoding the
antibacterial protein cathelicidin contains a functional VDR
response element and expression appears to be stimulated by
the precursor of 1,25D3 namely 25D3 binding to VDR.
Signalling via the toll-like 2/1 receptor induces the expression
of VDR and the gene that encodes 1α-hydroxylase
(CYP27B1) within monocytes [62]. Monocytes are able to
differentiate into either macrophages or dendritic cells and
dendritic cells can be either immunogenic or tolerogenic re-
garding their participation in an immune response. Overall
1,25D3 induces myeloid dendritic cells to become tolerogenic
by inhibiting their maturation and therefore the expression of
costimulatory molecules and IL-12 [63]. This, in turn, affects
their ability to present antigens to and stimulate T cells.
1,25D3 influences the behaviour of both T lymphocytes
and B lymphocytes. Early studies revealed that 1,25D3 leads
Fig. 2 Some of the influences of the most active metabolite of vitamin D
(1,25D3) on immune cells. The most active metabolite of vitamin D
1α,25-dihydroxyvitamin D3 (1,25D3) binds to the vitamin D (VDR)
receptor to regulate gene expression that, in turn and for example, either
drives or interferes with cell differentiation
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to T lymphocytes differentiating preferentially towards a T-
regulatory phenotype [64] and 1,25D3 together with steroids
stimulated the production of IL-10 by CD4+veCD25+ve regu-
latory T cells [65]. By contrast, 1,25D3 inhibits the secretion
of IL-2 by CD4+ve T helper 1 cells and their expansion [66]. In
these instances and again, we see the action of 1,25D3 altering
cytokine production to change the behaviour of immune cells.
Similarly, in vitro studies have shown that 1,25D3 increases
the secretion of the potent anti-inflammatory cytokine IL-10
by human dendritic cells leading to impaired activation of
alloreactive T lymphocytes [63]. Indeed, 1,25D3 suppresses
autoimmunity as seen for experimental autoimmune enceph-
alomyelitis in mice [67]. 1,25D3 appears to have little effect
on CD8+ve Tcells [68]. Since the 1980s, we have known that
1,25D3 inhibits B lymphocyte proliferation and differentia-
tion to plasma cells and memory cells, and consequentially
decreases antibody production [68–71].
The Implications to General Health
and of the Immune System
From all of the above, vitamin D is vital to the immune system
and its integrity and proper responsiveness are highly germane
to good health and the avoidance of risk of many different
diseases. As mentioned above, 1,25D3 can suppress autoim-
munity and, for example, vitamin D protects against the de-
velopment of immune-mediated type I diabetes mellitus [72].
A low level of vitamin D compared with healthy subjects and
VDR’s polymorphisms also correlates with other organ-
specific (e.g. multiple sclerosis, diabetes mellitus and primary
biliary cirrhosis) and systemic (e.g. systemic lupus erythema-
tosus and rheumatoid arthritis) autoimmune diseases [73] and
vitamin D supplementation has a therapeutic benefit in mouse
models of autoimmunity [73•, 74•]. Mechanistic studies sup-
port the viewpoint that there is dysregulation of dendritic cells,
regulatory T lymphocytes and T helper 1 cell maturation and
functionality in individuals who are genetically predisposed to
autoimmunity and who have a vitamin D deficiency [74•]. A
low level of vitamin D leads also to other health risks that
include osteoporosis, hypertension and muscle fatigue.
Around one billion people are vitamin D-deficient worldwide,
and to avoid the risks to health, the American Institute of
Medicine recommends taking 600 IU per day of vitamin D
up to the age of 70, and 800 IU if older. UK guidelines rec-
ommend vitamin D during winter to protect bone, teeth and
muscle, as sunlight is insufficient.
As mentioned above, 1,25D3 drives the growth arrest
and differentiation of leukaemia cell lines and the growth
arrest and apoptosis of a variety of other cancer cells
(reviewed in [75]). Additionally, 1,25D3 and derivatives
prevent several cancers in mouse models, with increasing
evidence from epidemiological studies in humans [76,
77••]. As mentioned above, 1,25D3 enhances the
secretion of IL4 by iNKT cells [56], and these cells may
play a role in immune surveillance against cancer.
However and regarding the use of 1,25D3 to treat leukae-
mia and other cancers, it is important to bear in mind that
the cancer stem cell theory states that most, if not all,
cancer arise is a tissue-specific stem cell [78]. Some ana-
logues of vitamin D are active against cancer stem cell–
like cells as least regarding reducing the expression of
stem cell genes by the HT-29 colorectal carcinoma cell
line [79].
Led by findings from the studies of the influence of 1,25D3
on myelopoiesis, the myeloid leukaemias and myelodysplasia
are perhaps the best therapeutic malignancy targets and there
are trials of inecalcitol, a 1,25D3 analogue, in AML and
chronic lymphocytic leukaemia and inecalcitol with
decitabine in AML. There are encouraging data from trials
of the use of vitamin D and its analogues in combination with
chemotherapy [80, 81], but generally, the outcomes are disap-
pointing. The fact is that calcaemic action of 1,25D3 and its
analogues used so far in cancer trials with chemotherapy limits
their dosage to a suboptimal level due to the risk of hypercal-
cemia, coma and cardiac arrest. A more potent and safer ana-
logue of 1,25D is therefore required to allow dosage escalation
to a therapeutic level. A non/weakly calcaemic analogue of
1,25D3 would also provide a better prophylactic than vitamin
D regarding enhancing immune-competence as D3 hydroxyl-
ation to 1,25D3 is often impaired in older people.
Analogues of Vitamin D that Are Selective in their
Action
There are several metabolites of vitamin D and hundreds
of analogues and the modifications to generate analogues
provided important information about structure-activity
relationships. A major advance in the field of vitamin D
research was the development of analogues of vitamin D
that separate the differentiating/anticancer and calcaemic
actions of 1,25D3. We elucidated some rules to achieving
this endeavour. A β-chair conformation of the A-ring is
essential for differentiating activity, as are hydrogen
bonds and the (24Ε) side-chain geometry. CD ring modi-
fication and a closo-carbonyl cluster at the side-chain di-
minish calcaemic action. A rigid and straight (24Ε) side
chain confers resistance to catabolism by the enzyme
CYP24A1 (reviewed in [82••]). Unquestionably, agents
with increased differentiating/anticancer potency and with
minimal calcaemic action provide a perfect tool for scien-
tific studies of haematopoiesis and a refined therapeutic,
as to the avoidance of the calcaemic action of 1,25D3.
Figure 3 shows some of the analogues of vitamin Ds
generated at the Pharmaceutical Research Institute in
Warsaw and potencies regarding their differentiating and
calcaemic actions. Some of the analogues have minimal
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residual calcaemic action, for example, PRI-5202.
Importantly, some of the analogues are substantially more
potent as differentiating agents as to their action on mye-
loid leukaemia cell lines than the parental hormone
1,25D3, including PRI-5202 that has a reduced calcaemic
action. The low calcaemic analogues are also effective
against AML cells in vitro and in animal models of dis-
ease [83•].
Unfinished Business Regarding the Action of 1,25D3
on Haematopoietic Cells
There are a number of unresolved issues regarding our under-
standing of the mode of action of 1,25D3 during ‘develop-
mental’ haematopoiesis and the influences on the immune cell
types. As mentioned above, 1,25D3 promotes monocyte/
macrophage as opposed to neutrophil development of normal
myeloid progenitors and the promyeloid cell line HL60.
However, we now know that the decision to develop along
the monocyte/macrophage pathway can occur within HSCs,
and does the influence of 1,25D3 extend to these cells and this
process? The data obtained using human CD34+ve
haematopoietic progenitors indicate that physiological levels
of 1,25D3 downregulate CD34 antigen and increase the num-
ber of monocyte-committed progenitors [84].
The mode of action of 1,25D3 to the differentiation per se
of haematopoietic cells is still in need of further clarification.
Many investigators hold the viewpoint that this biological
action is solely via ‘a genomic effect’, namely the 1,25D/
VDR-driven regulation of the gene transcription that is re-
quired for cell differentiation, for example CD14 expression
and macrophage differentiation. However and in addition to
this, 1,25D elicits rapid intracellular signals leading to the
activation of the RAS/RAF/ERK-MAP kinase signalling
pathway. The activation of this pathway within seconds or
minutes means that the signals are not attributable to VDR-
driven regulation of gene expression since transcription re-
quires at least a few hours. The rapid intracellular signals are
important to 1,25D3-driven differentiation of the promyeloid
cell line NB4 and nuclear events are not required [85]. At
present, the nature of a membrane receptor that might be re-
sponsible for the rapid response of cells to 1,25D3 is unclear.
A small proportion of a cell’s canonical VDR is at the cell
membrane [86] but this is not the sole reason for the
1,25D3-provoked rapid signals because they occur when in-
vestigators treated cells from VDR−/− mice 1,25D3 [87].
Other putative membrane receptors include the Membrane
Associated Rapid Response Steroid-binding protein
(MARRS) [88], megalin and cubilin ([89], reviewed in
[90]). Megalin and cubilin transport vitamin D, complexed
to its serum binding protein. Receptor endocytosis can gener-
ate rapid intracellular signals via the Rab5/PI3-kinase pathway
[91]. However and from knockout studies, we have excluded
the involvement of megalin and cubilin as to the differentiat-
ing potency and selectivity of our analogues of 1,25D3 [92].
Even so, an interplay between genomic events and rapid in-
tracellular signalling is likely to be important to how 1,25D3
brings about a change to the status of developing and mature
haematopoietic cells.
Perhaps we might exclude the calcaemic action of 1,25D3
as having a major role in the differentiating action of 1,25D3
because analogues that are weakly calcaemic are highly potent
Fig. 3 Structures of leading analogues of 1α,25-dihydroxyvitamin D2
and their activities. The analogues separated the differentiating and
calcaemic actions of 1,25D3 and some are highly potent differentiating
agents and very weakly calcaemic, for example, PRI-5202. The EC50 is
for differentiation of the promyeloid cell line HL60 to macrophages. We
treated mice with 0.3 μg/kg of 1,25D3 or analogues of 1α,25-
dihydroxyvitamin D2 every other day for 3 weeks and measured blood
calcium on day 21. The calcaemic action is graded weak (green) to high
as for 1,25D3 (red). VDR, vitamin D receptor, IC50 is the binding affinity
for VDR; EC50 is the concentration from dose response curves that
resulted in 50% of maximum differentiation
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differentiating agents (see Fig. 3). However, this leaves us
with another problem because the potent differentiating ana-
logues do not always bind to the ligand-binding domain of
VDR with higher affinity (see Fig. 3 and [93]). A possibility
that we favour is that our new analogues bind to a particular
pocket of the VDR ligand-binding domain leading to a partic-
ular conformational change that drives a selective change to
the behaviour of cells. Whether there is a separate ligand-
binding domain of VDR for the calcaemic action of 1,25D3
is also an uncertainty. The jury is still out on these matters
because the lack of availability of the full-length VDR crystal
structure hampers proper investigation. The use of truncated
VDR for crystallography has led to discrepancies between
affinity measurements and docking information.
Concluding Remarks
There has been a resurgence of interest in 1,25D3 and much is
unrelated to its classical and longstanding roles in regulating
bone health regarding calcium/phosphate homeostasis. Most
types of cells express VDR, and 1,25D3 and VDR regulate the
conduct of, in particular, monocyte/macrophage and iNKT
cell development and the functionality of many of the immune
end cells. We often think of this in terms of the regulation of
gene expression either directly or indirectly by activated nu-
clear VDR. However, 1,25D3 and analogues of 1,25D3 have
other interesting actions that are general as to an effect on
different cell types. These include influences on the
production/action of the haematopoietic cytokines that are es-
sential to the development and function of the bloods cells. In
fact, in many of the above examples of changes to the status or
functionality of blood cells, there is a link between the action
of 1,25D3 and a cytokine/cytokine receptor. In addition, some
analogues influence chromatin structure and the epigenetic
landscape [57] and regulate the expression of micro RNAs
[94] that might fine-tune the action of the cytokine receptors.
It is most reasonable to suggest that the level of intake of
vitamin D that various agencies and doctors have recommend-
ed is important to not only the health of the haematopoietic
cell system but also to that of the organism as a whole.
Important attributes to this interest and tools to providing a
better understanding of the actions of vitamin D are the ana-
logues of 1,25D3 that are weakly calcaemic. There is also the
prospect of applying the rules elucidated so far to eliminate the
calcaemic action from 1,25D3 whilst retaining highly potent
differentiating/anticancer actions. The use of existing and
newer analogues of 1,25D3, which are even more selective
and efficacious, may well lead to the prevention of the onset of
significant health problems, immune cell related or otherwise,
and provide a useful adjunct to cancer treatment. Primary
1,25D3 target genes allow the evaluation of subjects who
might benefit from supplementation of vitamin D and there
are appropriate transcriptomic biomarkers, for example,
upregu la t ion of the genes encod ing CD14 and
thrombomodulin [48].
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